

# Cynthia Levy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/238363/publications.pdf>

Version: 2024-02-01

89  
papers

3,188  
citations

201674

27  
h-index

168389

53  
g-index

90  
all docs

90  
docs citations

90  
times ranked

2877  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	3.9	15
2	Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 995-1005.	2.3	9
3	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	4.4	15
4	Anti-mitochondrial Antibody-Negative Primary Biliary Cholangitis Is Part of the Same Spectrum of Classical Primary Biliary Cholangitis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3305-3312.	2.3	9
5	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. <i>Liver International</i> , 2022, 42, 112-123.	3.9	31
6	Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. <i>Annals of Hepatology</i> , 2022, 27, 100546.	1.5	6
7	Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 76, 75-85.	3.7	22
8	Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis. <i>Liver International</i> , 2022, 42, 384-393.	3.9	7
9	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 607-614.	3.9	26
10	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
11	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 353-364.	3.7	36
12	EASL Clinical Practice Guidelines on sclerosing cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 761-806.	3.7	84
13	Use of Butorphanol as Treatment for Cholestatic Itch. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1693-1699.	2.3	10
14	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1105-1116.	7.3	14
15	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	4.4	25
16	Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. <i>Hepatology</i> , 2021, 73, 887-889.	7.3	3
17	Safety of fibrates in cholestatic liver diseases. <i>Liver International</i> , 2021, 41, 1335-1343.	3.9	25
18	Safety considerations for the management of cholestatic itch. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 915-924.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis. <i>Hepatology</i> , 2021, 74, 879-891.	7.3	36
20	Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1913-1923.	0.4	28
21	Validating a novel algorithm to identify patients with autoimmune hepatitis in an administrative database. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1168-1174.	1.9	4
22	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. <i>Canadian Liver Journal</i> , 2021, 4, 401-425.	0.9	1
23	Is Ursodeoxycholic Acid Really a Posttransplant Panacea?. <i>Liver Transplantation</i> , 2021, 27, 791-793.	2.4	1
24	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021, 73, 2099-2109.	7.3	56
25	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 1344-1354.	3.7	77
26	REPLY:. <i>Hepatology</i> , 2021, 74, 2308-2308.	7.3	0
27	REPLY:. <i>Hepatology</i> , 2021, 74, 2322-2323.	7.3	0
28	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	3.7	37
29	Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 818089.	3.5	4
30	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	4.4	57
31	Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria. <i>Genetics in Medicine</i> , 2020, 22, 590-597.	2.4	8
32	Gender Differences in Hepatology Medical Literature. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3014-3022.	2.3	13
33	Editorial: biochemical responses do not tell the whole story in primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 177-178.	3.7	0
34	Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. <i>Liver International</i> , 2020, 40, 382-392.	3.9	19
35	Role of Antinuclear Antibodies in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1604-1606.	0.4	8
36	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. <i>Journal of Hepatology</i> , 2020, 73, S464-S465.	3.7	7

#	ARTICLE	IF	CITATIONS
37	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 94-101.	3.7	111
38	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	4.4	18
39	Novel Therapies for Managing Cholestasis. <i>Clinical Liver Disease</i> , 2020, 15, 95-99.	2.1	3
40	Hispanic Patients with Primary Biliary Cholangitis Have Decreased Access to Care Compared to Non-Hispanics. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-6.	1.4	6
41	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 394-419.	7.3	507
42	UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 232-241.	0.8	8
43	Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. <i>Journal of Autoimmunity</i> , 2019, 101, 26-34.	6.5	40
44	Use of Fenofibrate for patients with primary Sclerosing Cholangitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e33-e36.	1.5	3
45	Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 830-839.	3.7	43
46	Hepatic Sarcoidosis: Natural History and Management Implications. <i>Frontiers in Medicine</i> , 2019, 6, 232.	2.6	29
47	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> , 2019, 69, 684-698.	7.3	121
48	Novel Therapies for Cholestatic Liver Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 493-496.	0.1	3
49	Primary Biliary Cholangitis: A New Era. <i>Clinics in Liver Disease</i> , 2018, 22, xiii-xiv.	2.1	0
50	A real-world observational cohort of patients with primary biliary cholangitis: TARGET primary biliary cholangitis study design and rationale. <i>Hepatology Communications</i> , 2018, 2, 484-491.	4.3	12
51	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 591-593.	4.4	20
52	Itching to Know: Role of Fibrates in PBC. <i>American Journal of Gastroenterology</i> , 2018, 113, 56-57.	0.4	3
53	Evolving role of obeticholic acid in primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1666-1668.	7.3	5
54	Cholestatic liver diseases: new targets, new therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878740.	3.2	61

#	ARTICLE	IF	CITATIONS
55	Portal Cavernoma Mimicking Pancreatic Malignancy. <i>ACG Case Reports Journal</i> , 2018, 5, e15.	0.4	1
56	Novel and emerging therapies for cholestatic liver diseases. <i>Liver International</i> , 2018, 38, 1520-1535.	3.9	53
57	Understanding and Treating Pruritus in Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 517-532.	2.1	21
58	Ethnic and Racial Differences in Autoimmune Liver Diseases. <i>Current Hepatology Reports</i> , 2018, 17, 135-142.	0.9	1
59	Primary Biliary Cholangitis Guidance Update: Implications for Liver Transplantation. <i>Liver Transplantation</i> , 2018, 24, 1508-1511.	2.4	7
60	Update in the Care and Management of Patients with Primary Sclerosing Cholangitis. <i>Current Gastroenterology Reports</i> , 2018, 20, 29.	2.5	3
61	Primary Biliary Cholangitis. , 2018, , 610-625.e3.		0
62	Primary biliary cholangitis: Treatment options finally expand. <i>Hepatology</i> , 2017, 65, 1405-1407.	7.3	3
63	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
64	Cholestatic Liver Diseases After Liver Transplant. <i>Clinics in Liver Disease</i> , 2017, 21, 403-420.	2.1	14
65	Seladelpar (MBX-8025), a selective PPAR- $\gamma$ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 716-726.	8.1	126
66	Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2017, 37, 305-313.	3.6	32
67	Endoscopic Management of Primary Sclerosing Cholangitis. <i>Annals of Hepatology</i> , 2017, 16, 842-850.	1.5	15
68	Fibrates for Primary Biliary Cholangitis: What's All the Hype?. <i>Annals of Hepatology</i> , 2017, 16, 704-706.	1.5	3
69	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> , 2016, 64, 189-199.	7.3	101
70	Can we avoid primary sclerosing cholangitis recurrence?. <i>Liver Transplantation</i> , 2016, 22, 12-13.	2.4	1
71	FXR Agonists: From Bench to Bedside, a Guide for Clinicians. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3395-3404.	2.3	22
72	Novel Therapies on Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2016, 20, 113-130.	2.1	8

#	ARTICLE	IF	CITATIONS
73	Advances in Cholestatic Liver Diseases. Clinics in Liver Disease, 2016, 20, xiii-xiv.	2.1	0
74	Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. Arquivos De Gastroenterologia, 2015, 52, 15-46.	0.8	11
75	Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 296-306.	1.5	69
76	Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2015, 6, e109.	2.5	23
77	Medical management of primary sclerosing cholangitis. Clinical Liver Disease, 2014, 3, 48-51.	2.1	3
78	Hispanics With Primary Biliary Cirrhosis Are More Likely to Have Features of Autoimmune Hepatitis and Reduced Response to Ursodeoxycholic Acid Than Non-Hispanics. Clinical Gastroenterology and Hepatology, 2014, 12, 1398-1405.	4.4	55
79	Ethnicity predicts metabolic syndrome after liver transplant. Hepatology International, 2013, 7, 741-748.	4.2	8
80	Tu1002 Fenofibrate Improves Alkaline Phosphatase in Primary Sclerosing Cholangitis. Gastroenterology, 2013, 144, S-1028-S-1029.	1.3	10
81	Primary Biliary Cirrhosis. Clinics in Liver Disease, 2013, 17, 229-242.	2.1	27
82	Cholestatic Liver Diseases. Clinics in Liver Disease, 2013, 17, xiii-xiv.	2.1	1
83	Primary Biliary Cirrhosis is More Severe in Overweight Patients. Journal of Clinical Gastroenterology, 2013, 47, e28-e32.	2.2	38
84	Liver Transplant: Reaching the Half Century. Clinics in Liver Disease, 2011, 15, xi-xii.	2.1	1
85	Recurrent and De Novo Autoimmune Liver Diseases. Clinics in Liver Disease, 2011, 15, 859-878.	2.1	44
86	Prevalence and Predictors of Esophageal Varices in Patients With Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2007, 5, 803-808.	4.4	48
87	Primary Sclerosing Cholangitis: Epidemiology, Natural History, and Prognosis. Seminars in Liver Disease, 2006, 26, 022-030.	3.6	74
88	The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2005, 50, 1734-1740.	2.3	300
89	Primary Biliary Cholangitis. Current Treatment Options in Gastroenterology, 0, , .	0.8	0